Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Schizophrenia

  Free Subscription


Articles published in Neuropsychopharmacology

Retrieve available abstracts of 53 articles:
HTML format



Single Articles


    March 2022
  1. ALNAFISAH RS, Reigle J, Eladawi MA, O'Donovan SM, et al
    Assessing the effects of antipsychotic medications on schizophrenia functional analysis: a postmortem proteome study.
    Neuropsychopharmacology. 2022 Mar 30. pii: 10.1038/s41386-022-01310.
    PubMed     Abstract available


  2. ZHAO Q, Cao H, Zhang W, Li S, et al
    A subtype of institutionalized patients with schizophrenia characterized by pronounced subcortical and cognitive deficits.
    Neuropsychopharmacology. 2022 Mar 8. pii: 10.1038/s41386-022-01300.
    PubMed     Abstract available


  3. TSITSIPA E, Rogers J, Casalotti S, Belessiotis-Richards C, et al
    Selective 5HT3 antagonists and sensory processing: a systematic review.
    Neuropsychopharmacology. 2022;47:880-890.
    PubMed     Abstract available


  4. DAO M, Stoveken HM, Cao Y, Martemyanov KA, et al
    The role of orphan receptor GPR139 in neuropsychiatric behavior.
    Neuropsychopharmacology. 2022;47:902-913.
    PubMed     Abstract available


    February 2022
  5. SEHATPOUR P, Javitt DC, De Baun HM, Carlson M, et al
    Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.
    Neuropsychopharmacology. 2022;47:711-718.
    PubMed     Abstract available


    January 2022
  6. KIMOTO S, Hashimoto T, Berry KJ, Tsubomoto M, et al
    Expression of actin- and oxidative phosphorylation-related transcripts across the cortical visuospatial working memory network in unaffected comparison and schizophrenia subjects.
    Neuropsychopharmacology. 2022 Jan 15. pii: 10.1038/s41386-022-01274.
    PubMed     Abstract available


  7. CARREIRA FIGUEIREDO I, Borgan F, Pasternak O, Turkheimer FE, et al
    White-matter free-water diffusion MRI in schizophrenia: a systematic review and meta-analysis.
    Neuropsychopharmacology. 2022 Jan 15. pii: 10.1038/s41386-022-01272.
    PubMed     Abstract available


    November 2021
  8. KIEMES A, Gomes FV, Cash D, Uliana DL, et al
    GABAA and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophrenia.
    Neuropsychopharmacology. 2021 Nov 6. pii: 10.1038/s41386-021-01213.
    PubMed     Abstract available


    October 2021
  9. KIM M, Lee TH, Park H, Moon SY, et al
    Thalamocortical dysrhythmia in patients with schizophrenia spectrum disorder and individuals at clinical high risk for psychosis.
    Neuropsychopharmacology. 2021 Oct 4. pii: 10.1038/s41386-021-01180.
    PubMed     Abstract available


  10. PELIN H, Ising M, Stein F, Meinert S, et al
    Identification of transdiagnostic psychiatric disorder subtypes using unsupervised learning.
    Neuropsychopharmacology. 2021;46:1895-1905.
    PubMed     Abstract available


    September 2021
  11. TUOMINEN L, Romaniuk L, Milad MR, Goff DC, et al
    Impairment in acquisition of conditioned fear in schizophrenia.
    Neuropsychopharmacology. 2021 Sep 29. pii: 10.1038/s41386-021-01193.
    PubMed     Abstract available


  12. MILLARD SJ, Bearden CE, Karlsgodt KH, Sharpe MJ, et al
    The prediction-error hypothesis of schizophrenia: new data point to circuit-specific changes in dopamine activity.
    Neuropsychopharmacology. 2021 Sep 29. pii: 10.1038/s41386-021-01188.
    PubMed     Abstract available


  13. EUM S, Hill SK, Alliey-Rodriguez N, Stevenson JM, et al
    Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders.
    Neuropsychopharmacology. 2021;46:1802-1810.
    PubMed     Abstract available


  14. LAM M, Chen CY, Ge T, Xia Y, et al
    Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics.
    Neuropsychopharmacology. 2021;46:1788-1801.
    PubMed     Abstract available


    August 2021
  15. ABDALLAH CG, Mason GF
    Novel approaches to estimate prefrontal synaptic strength in vivo in humans: of relevance to depression, schizophrenia, and ketamine.
    Neuropsychopharmacology. 2021 Aug 2. pii: 10.1038/s41386-021-01122.
    PubMed    


  16. BRALTEN J, Mota NR, Klemann CJHM, De Witte W, et al
    Genetic underpinnings of sociability in the general population.
    Neuropsychopharmacology. 2021;46:1627-1634.
    PubMed     Abstract available


    July 2021
  17. SMUCNY J, Dienel SJ, Lewis DA, Carter CS, et al
    Mechanisms underlying dorsolateral prefrontal cortex contributions to cognitive dysfunction in schizophrenia.
    Neuropsychopharmacology. 2021 Jul 20. pii: 10.1038/s41386-021-01089.
    PubMed     Abstract available


  18. FERRARELLI F, Phillips ML
    PFC neuromodulation with theta burst stimulation to impact behavior and neural network activity in schizophrenia and bipolar disorder.
    Neuropsychopharmacology. 2021 Jul 7. pii: 10.1038/s41386-021-01086.
    PubMed    


  19. GOLDWASER EL, Chiappelli J, Kvarta MD, Du X, et al
    White matter in prolonged glucocorticoid response to psychological stress in schizophrenia.
    Neuropsychopharmacology. 2021 Jul 1. pii: 10.1038/s41386-021-01077.
    PubMed     Abstract available


    June 2021
  20. AVRAM M, Grothe MJ, Meinhold L, Leucht C, et al
    Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia.
    Neuropsychopharmacology. 2021 Jun 29. pii: 10.1038/s41386-021-01070.
    PubMed     Abstract available


  21. TRONCHIN G, Akudjedu TN, Ahmed M, Holleran L, et al
    Correction to: Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment.
    Neuropsychopharmacology. 2021 Jun 24. pii: 10.1038/s41386-021-01062.
    PubMed    


    May 2021
  22. MODINOS G, Richter A, Egerton A, Bonoldi I, et al
    Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes.
    Neuropsychopharmacology. 2021 May 3. pii: 10.1038/s41386-021-01019.
    PubMed     Abstract available


    April 2021
  23. SEITZ-HOLLAND J, Seethaler M, Makris N, Rushmore J, et al
    The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study.
    Neuropsychopharmacology. 2021 Apr 8. pii: 10.1038/s41386-021-00997.
    PubMed     Abstract available


    March 2021
  24. WENZEL J, Haas SS, Dwyer DB, Ruef A, et al
    Cognitive subtypes in recent onset psychosis: distinct neurobiological fingerprints?
    Neuropsychopharmacology. 2021 Mar 15. pii: 10.1038/s41386-021-00963.
    PubMed     Abstract available


  25. PENZEL N, Antonucci LA, Betz LT, Sanfelici R, et al
    Association between age of cannabis initiation and gray matter covariance networks in recent onset psychosis.
    Neuropsychopharmacology. 2021 Mar 3. pii: 10.1038/s41386-021-00977.
    PubMed     Abstract available


    February 2021
  26. CHOPRA S, Fornito A, Francey SM, O'Donoghue B, et al
    Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: A Longitudinal, Randomised, Triple-blind, Placebo-controlled MRI Study.
    Neuropsychopharmacology. 2021 Feb 26. pii: 10.1038/s41386-021-00980.
    PubMed     Abstract available


  27. MAAS DA, Eijsink VD, van Hulten JA, Panic R, et al
    Antioxidant treatment ameliorates prefrontal hypomyelination and cognitive deficits in a rat model of schizophrenia.
    Neuropsychopharmacology. 2021 Feb 9. pii: 10.1038/s41386-021-00964.
    PubMed     Abstract available


    January 2021
  28. SMUCNY J, Tully LM, Howell AM, Lesh TA, et al
    Schizophrenia and bipolar disorder are associated with opposite brain reward anticipation-associated response.
    Neuropsychopharmacology. 2021 Jan 15. pii: 10.1038/s41386-020-00940.
    PubMed     Abstract available


  29. LIANG S, Wang Q, Greenshaw AJ, Li X, et al
    Aberrant triple-network connectivity patterns discriminate biotypes of first-episode medication-naive schizophrenia in two large independent cohorts.
    Neuropsychopharmacology. 2021 Jan 6. pii: 10.1038/s41386-020-00926.
    PubMed     Abstract available


    December 2020
  30. STERTZ L, Di Re J, Pei G, Fries GR, et al
    Convergent genomic and pharmacological evidence of PI3K/GSK3 signaling alterations in neurons from schizophrenia patients.
    Neuropsychopharmacology. 2020 Dec 7. pii: 10.1038/s41386-020-00924.
    PubMed     Abstract available


  31. QUINONES GM, Mayeli A, Yushmanov VE, Hetherington HP, et al
    Reduced GABA/glutamate in the thalamus of individuals at clinical high risk for psychosis.
    Neuropsychopharmacology. 2020 Dec 3. pii: 10.1038/s41386-020-00920.
    PubMed     Abstract available


    November 2020
  32. DESAI A, Benner L, Wu R, Gertsik L, et al
    Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia.
    Neuropsychopharmacology. 2020 Nov 17. pii: 10.1038/s41386-020-00908.
    PubMed     Abstract available


    October 2020
  33. HAAS SS, Antonucci LA, Wenzel J, Ruef A, et al
    A multivariate neuromonitoring approach to neuroplasticity-based computerized cognitive training in recent onset psychosis.
    Neuropsychopharmacology. 2020 Oct 7. pii: 10.1038/s41386-020-00877.
    PubMed     Abstract available


  34. VALLE-LEON M, Callado LF, Aso E, Cajiao-Manrique MM, et al
    Decreased striatal adenosine A2A-dopamine D2 receptor heteromerization in schizophrenia.
    Neuropsychopharmacology. 2020 Oct 3. pii: 10.1038/s41386-020-00872.
    PubMed     Abstract available


    September 2020
  35. TAMMINGA CA, Clementz BA, Pearlson G, Keshavan M, et al
    Biotyping in psychosis: using multiple computational approaches with one data set.
    Neuropsychopharmacology. 2020 Sep 26. pii: 10.1038/s41386-020-00849.
    PubMed     Abstract available


  36. GALLEGO JA, Blanco EA, Morell C, Lencz T, et al
    Complement component C4 levels in the cerebrospinal fluid and plasma of patients with schizophrenia.
    Neuropsychopharmacology. 2020 Sep 22. pii: 10.1038/s41386-020-00867.
    PubMed     Abstract available


  37. VERONESE M, Santangelo B, Jauhar S, D'Ambrosio E, et al
    A potential biomarker for treatment stratification in psychosis: evaluation of an [(18)F] FDOPA PET imaging approach.
    Neuropsychopharmacology. 2020 Sep 22. pii: 10.1038/s41386-020-00866.
    PubMed     Abstract available


  38. SWERDLOW NR, Bhakta S, Talledo J, Kotz J, et al
    Memantine effects on auditory discrimination and training in schizophrenia patients.
    Neuropsychopharmacology. 2020 Sep 22. pii: 10.1038/s41386-020-00865.
    PubMed     Abstract available


  39. MYLONAS D, Baran B, Demanuele C, Cox R, et al
    The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a randomized clinical trial.
    Neuropsychopharmacology. 2020 Sep 12. pii: 10.1038/s41386-020-00833.
    PubMed     Abstract available


    August 2020
  40. NAKAO K, Singh M, Sapkota K, Hagler BC, et al
    GSK3beta inhibition restores cortical gamma oscillation and cognitive behavior in a mouse model of NMDA receptor hypofunction relevant to schizophrenia.
    Neuropsychopharmacology. 2020 Aug 28. pii: 10.1038/s41386-020-00819.
    PubMed     Abstract available


  41. KOSHIYAMA D, Miyakoshi M, Joshi YB, Molina JL, et al
    A distributed frontotemporal network underlies gamma-band synchronization impairments in schizophrenia patients.
    Neuropsychopharmacology. 2020 Aug 22. pii: 10.1038/s41386-020-00806.
    PubMed     Abstract available


  42. MURPHY M, Ongur D
    EEG microstate sequences suggest abnormally chaotic brain dynamics in psychosis.
    Neuropsychopharmacology. 2020 Aug 14. pii: 10.1038/s41386-020-00800.
    PubMed    


    July 2020
  43. CHENG PWC, Chang WC, Lo GG, Chan KWS, et al
    The role of dopamine dysregulation and evidence for the transdiagnostic nature of elevated dopamine synthesis in psychosis: a positron emission tomography (PET) study comparing schizophrenia, delusional disorder, and other psychotic disorders.
    Neuropsychopharmacology. 2020 Jul 1. pii: 10.1038/s41386-020-0740.
    PubMed     Abstract available


  44. QIN Z, Zhang L, Cruz SA, Stewart AFR, et al
    Activation of tyrosine phosphatase PTP1B in pyramidal neurons impairs endocannabinoid signaling by tyrosine receptor kinase trkB and causes schizophrenia-like behaviors in mice.
    Neuropsychopharmacology. 2020 Jul 1. pii: 10.1038/s41386-020-0755.
    PubMed     Abstract available


    June 2020
  45. BOUDEWYN M, Scangos K, Ranganath C, Carter CS, et al
    Using prefrontal transcranial direct current stimulation (tDCS) to enhance proactive cognitive control in schizophrenia.
    Neuropsychopharmacology. 2020 Jun 30. pii: 10.1038/s41386-020-0750.
    PubMed     Abstract available


  46. XIA Y, Zhang Z, Lin W, Yan J, et al
    Modulating microglia activation prevents maternal immune activation induced schizophrenia-relevant behavior phenotypes via arginase 1 in the dentate gyrus.
    Neuropsychopharmacology. 2020 Jun 29. pii: 10.1038/s41386-020-0743.
    PubMed     Abstract available


  47. CLARK SD, Van Snellenberg JX, Lawson JM, Abi-Dargham A, et al
    Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials.
    Neuropsychopharmacology. 2020 Jun 9. pii: 10.1038/s41386-020-0730.
    PubMed     Abstract available


    May 2020
  48. TROUDET R, Ali WBH, Bacq-Daian D, Rossum IWV, et al
    Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses.
    Neuropsychopharmacology. 2020 May 25. pii: 10.1038/s41386-020-0703.
    PubMed     Abstract available


  49. KANTROWITZ JT, Grinband J, Goff DC, Lahti AC, et al
    Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers.
    Neuropsychopharmacology. 2020 May 13. pii: 10.1038/s41386-020-0706.
    PubMed     Abstract available


  50. BUSTILLO JR, Upston J, Mayer G, Jones T, et al
    Glutamatergic hypo-function in the left superior and middle temporal gyri in early schizophrenia: a data-driven three-dimensional proton spectroscopic imaging study.
    Neuropsychopharmacology. 2020 May 13. pii: 10.1038/s41386-020-0707.
    PubMed     Abstract available


    April 2020
  51. XIA L, Liu L, Hong X, Wang D, et al
    One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia.
    Neuropsychopharmacology. 2020 Apr 29. pii: 10.1038/s41386-020-0685.
    PubMed     Abstract available


  52. YAO L, Li F, Liu J, Liao W, et al
    Correction: Functional brain networks in never-treated and treated long-term Ill schizophrenia patients.
    Neuropsychopharmacology. 2020 Apr 17. pii: 10.1038/s41386-020-0673.
    PubMed     Abstract available


  53. TRONCHIN G, Akudjedu TN, Ahmed M, Holleran L, et al
    Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment.
    Neuropsychopharmacology. 2020 Apr 8. pii: 10.1038/s41386-020-0665.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: